Last quarter (Q ), Endocan's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Endocan's net income was $-234.14K. See Endocan’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Apr 22	Oct 21	Oct 20	Oct 19	Oct 18
Total Revenue	-	-	-	-	-	$ -12.00K
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	$ -12.00K
Operating Expense	$ -801.49K	$ -5.35M	$ 333.73K	$ -314.24K	$ -78.08K	$ -151.01K
Operating Income	$ -801.49K	$ -5.35M	$ -333.73K	$ -314.24K	$ -78.08K	-
Net Non Operating Interest Income Expense	$ 1.71K	$ 12.34K	-	-	-	-
Other Income Expense	$ 14.50K	$ -319.48K	$ 79.25K	-	-	$ 33.76K
Pretax Income	$ -785.27K	$ -5.66M	$ -254.47K	$ -314.24K	$ -78.08K	$ -129.25K
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -783.16K	$ -5.65M	$ -254.47K	$ -314.24K	$ -78.08K	-
Basic EPS	$ -0.03	$ -0.16	$ -0.01	$ -0.14	-	$ 0.06
Diluted EPS	$ -0.03	$ -0.16	$ -0.01	-	-	-
Basic Average Shares	$ 101.75M	$ 36.52M	$ 33.02M	$ 4.66M	-	$ 2.32M
Diluted Average Shares	$ 101.75M	$ 36.52M	$ 33.02M	$ 4.66M	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ -801.49K	$ -5.35M	$ -333.73K	-	-	-
Net Income From Continuing And Discontinued Operation	$ -783.16K	$ -5.65M	$ -254.47K	$ -314.24K	$ -78.08K	$ -129.25K
Normalized Income	$ -785.27K	$ -5.66M	$ -254.47K	$ -314.24K	$ -78.08K	$ -129.25K
Interest Expense	-	-	-	-	-	-
EBIT	$ -786.99K	$ -5.67M	$ -254.47K	$ -314.24K	$ -78.08K	$ -129.25K
EBITDA	$ -255.34K	-	-	$ -314.24K	$ -78.08K	$ -129.25K

Currency in USD

Endocan Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing